每年研究成果
每年研究成果
- 5結果
搜尋結果
-
2020
Corrigendum to “1,4-Naphthoquinones as inhibitors of Itch, a HECT domain-E3 ligase, and tumor growth suppressors in multiple myeloma” [Eur. J. Med. Chem. 140 (2017) 84–91](S0223523417306931)(10.1016/j.ejmech.2017.09.011)
Liu, Y. M., HuangFu, W. C., Huang, H. L., Wu, W. C., Chen, Y. L., Yen, Y., Huang, H. L., Nien, C. Y., Lai, M. J., Pan, S. L. & Liou, J. P., 9月 15 2020, 於: European Journal of Medicinal Chemistry. 202, 112633.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
2019
Correction to: Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway (Journal of Biomedical Science (2019) 26 (96) DOI: 10.1186/s12929-019-0588-8)
Wakabayashi, G., Lee, Y. C., Luh, F., Kuo, C. N., Chang, W. C. & Yen, Y., 12月 23 2019, 於: Journal of Biomedical Science. 26, 1, 98.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
2018
FDA guidance for next generation sequencing-based testing: balancing regulation and innovation in precision medicine
Luh, F. & Yen, Y., 12月 1 2018, 於: npj Genomic Medicine. 3, 1, 28.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
17 引文 斯高帕斯（Scopus） -
2015
Correction: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy(PLoS ONE (2015) 10:3 (e0121207) 10.1371/journal.pone.0121207)
Lee, Y. H., Liu, X., Qiu, F., O'Connor, T. R., Yen, Y. & Ann, D. K., 4月 13 2015, 於: PLoS ONE. 10, 4, 0124853.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
2 引文 斯高帕斯（Scopus） -
2011
Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma (Molecular and Cellular Proteomics (2011) 10, (1-13))
Chen, T., Xie, G., Wang, X., Fan, J., Qui, Y., Zheng, X., Qi, X., Cao, Y., Su, M., Wang, X., Xu, L. X., Yen, Y., Liu, P. & Jia, W., 11月 2011, 於: Molecular and Cellular Proteomics. 10, 11研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
47 引文 斯高帕斯（Scopus）